Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
68.64 USD | +0.04% | -2.95% | -15.27% |
07-01 | HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study | MT |
07-01 | HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.27% | 85.48B | |
+56.86% | 815B | |
+43.90% | 641B | |
-6.57% | 352B | |
+17.32% | 314B | |
+9.94% | 303B | |
+16.08% | 242B | |
+2.29% | 224B | |
+13.96% | 218B | |
+7.98% | 168B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc., Q2 2023 Earnings Call, Aug 03, 2023